Soligenix to work with University of Hawaii, Hawaii Biotech on Ebola; Medigene's dendritic cell vaccines receive patent extention;

> Princeton, NJ-based Soligenix inked a collaboration agreement with the University of Hawaii at Manoa and Hawaii Biotech to work on a heat stable Ebola vaccine. Release

> The U.S. Patent Office extended Medigene's patent for dendritic cell vaccines to 2031. Brief

> Noting a potential for a hypertension vaccine, researchers found in a study of rats that three needless injections delivered lowered blood pressure for up to six months. More

> Research published in mBio suggests a protein called Niemann-Pick C1 to be the "Achilles' heel" of Ebola. More

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.